Samuel lab publications

Selected highlight publications

1. Charoenphannathon JS, Royce SG, Higham Y, Bourke JE, Samuel CS*. 2026. Therapeutic targeting of bleomycin-induced pulmonary fibrosis by human bone marrow MSC-derived extracellular vesicles and/or pirfenidone: impact of sex in mature adult mice. British Journal of Pharmacology 183, 5423-5439.
2. Somanader-Livera, Wei C, Wang C, Li Y, Ferens D, Salimova E, Selomulya C, Hossain MA, Samuel CS*, Chakraborty A*. 2025. Immune cell uptake of glycinated nanoparticles conjugated to anti-fibrotic peptides enables their prolonged activity and oral administration. Journal of Biomedical Science 32, 104.
3. Royce SG, Erdem C, Mao W, Wang Y, De Borgo MP, Widdop RE*, Samuel CS*.2025. The novel AT₂R receptor ligand, b-pro⁷ Ang III, induces equivalent anti-fibrotic effects to Compound 21 but broader anti-fibrotic effects than pirfenidone in mice with bleomycin-induced pulmonary fibrosis. Clinical Science 139, 809-824.
4. Li Y, Hunter A, Wakeel MM, Sun G, Lau RWK, Broughton BRS, Pino IEO, Deng Z, Zhang T, Murthi P, Del Borgo MP, Widdop RE, Polo JM, Ricardo SD*, Samuel CS*. 2024. The renoprotective efficacy and safety of genetically-engineered human bone marrow-derived mesenchymal stromal cell expressing anti-fibrotic cargo. Stem Cell Research & Therapy 15, 375.
5. Chakraborty A, Wang C, Hodgson-Garms M, Broughton BRS, Frith JE, Kelly K, Samuel CS*. 2024. Induced pluripotent stem cell-derived mesenchymal stem cells reverse bleomycin-injured pulmonary fibrosis and related lung stiffness. Biomedicine & Pharmacotherapy 178, 117259.
6. Truong S, Bonnici B, Rupasinghe S, Kemp-Harper BK, Samuel CS*, Broughton BRS*. 2023. Post-stroke administration of H2 relaxin reduces functional deficits, neuronal apoptosis and immune cell infiltration into the mouse brain. Pharmacological Research 187, 106611.

*Corresponding author.

Additional publications

A full list of Samuel  Lab publications can be viewed on PubMed.